Suven Life Sciences to file IND on Alzheimer disease

Hyderabad, Apr 29 (UNI) Suven Life Sciences, a Hyderabad-based Life Sciences company, today said that it is in final phases of filing its first Investigational New Drug (IND) application with USFDA during this year in the therapeutic area of CNS focusing on Alzheimer's disease.

During the year, Suven spent 20 per cent of its revenue on R&D and has so far filed 32 product patents, a company release said here.

With 100 per cent growth in the net profit for the financial year 2005-06, the total income of the company stood at Rs. 8293.90 lacs, registering a growth of 36 per cent, against the total income of Rs 6077.93 lacs of the previous year. The net profit is at Rs 763.91 lacs at 100 per cent, up against the net of Rs 379.72 lacs for the previous year.

''There is a significant growth in exports by 95 per cent and domestic sales by 51 per cent. Quarter on Quarter basis the growth in total income stood at 40 per cent and growth in the net profit stood at 25 per cent, the release added.

UNI DB KVV 1840